Reddit Posts
2 “Strong Buy” Penny Stocks With Over 400% Upside on the Horizon
Rockets that are loaded: STAB, CYRN, SATL, DRTS, SKYH, CYN, BWV, MLTX, PTPI, ALLG
$THCA - Low Float SPAC near NAV, with squeeze potential
Real Potential $ISPO 2.0 -- $DRTS Moon shot incoming!
DRTS is an early candidate to a squeeze!! Buy now get paid in a week.
$DRTS Annual Report “In Coming Days” Will include share breakdown
Mentions
DRTSW. About 30% undervalued compared to parent DRTS, which is currently already beginning to breakout. Check my comments from last two days for summary
OPTT, SLS buying. MIGI and DRTS holding.
Accumulating DRTS is the way!
Long term- Both coincidentally the same price right now just out of penny range, but I’m accumulating DRTS and KRKNF. Short/medium term - SLS and MIGI are both very high potential
Take a look at the DRTS stock sub or my comments this morning.. too busy to make a combined post but I legitimately think DRTSW is the best high upside play out there this week.
I know SLS is taking the headlines but have a look at DRTS as well
I suggest you consider DRTS, it’s worth researching
Research the M&A that happened in the last year, you’ll see real money is flowing back and the valuations are rising. To name a few tickers I personally mentioned here this year: OBIO (at 2.40), ATAI (at 2.05), CMPS (~3), MRVI (2.20), all had even higher highs. The only one of those I’m still holding is OBIO, but the stock I’m really high and long on is DRTS
The one stock missing is DRTS, was a penny stock until recently but not any more. Get ready to see it a lot in 2026
**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** FDA Breakthrough Device Designation FDA TAP program inclusion FDA MDSAP certification FDA IDE’s for five cancers and counting Including FDA PHASE 3 completion for one indication in H1 2026 And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) FDA approval for commercial factory in the US, with other factories built and more in planing 100% tumor response rate in early FDA trials Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… Activates immune system 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy… and of course Japan where they are expected approval) Patents, IP and more…
**Upcoming catalyst for DRTS** **PMDA approval in Japan** Expected to be announced any day in the coming weeks **GBM FDA trial** Recently it was announced Alpha Tau has successfully treated the first GBM patient, historic news, with more patients and updates coming every month **FDA Pancreas trial** Earlier it was announced that Alpha Tau has successfully treated a Pancreatic Cancer patient as well, after successfully completing a Pancreatic Cancer study with tens of patients in Canada. Progress and updates from the Pancreas trial will be shared along the way **Phase 3 recruitment completion for cSCC** H1 2026 The early results are amazing **cSCC FDA approval submission** H2 2026 **New FDA trials launching** Most recently prostate, while next could be head & neck **Commercial manufacturing facility completion** Recently approved by the FDA **Keytruda trial for combination therapy** Updates from combination trials with Merck’s Keytruda, exploring systemic and metastatic potential **Other stock related events** Potential strategic partnerships or licensing deals, enabled by regulatory and manufacturing readiness. Investor re ratings, transitioning from pre revenue clinical stage to commercial oncology company is a major re-rating moment. Future label expansions leveraging existing approvals and platform scalability.
While we wait, I could tell you there’s a lot to be excited about going into 2026, everything is lining up perfectly for DRTS. Starting in January with the expected PMDA approval announcement, presenting two Alpha DaRT Pancreatic Cancer Abstracts at ASCO GI Symposium on January 8-10 in San Francisco, presenting at the J.P. Morgan 2026 Healthcare Conference on January 15, updates from trials and more all in the first month of the year
That’s where the squeeze finder can help (we spoke about it just yesterday) u/squeeze-finder could you please give a short report on DRTS here? And is there any way to know if there are more sophisticated shorts that aren’t reported?
Think look good here, but there is no way to figure out how many shares are really shorts in DRTS
Someone invited me to this DRTS sub. I believe this someone wants to pump this stock
Finally I’ll have success with one SPAC this DRTS, maybe I’ll make back the losses from the other SPACs
Not a bot - it's me :) I checked and DRTS is less than 1% short so not gonna show up in our Database. Sorry !
I’m very long DRTS. Check my reliability and track record before you go about accusing Also it’s trading at highs it hasn’t seen in years (SP and volume) so anyone trying to unload bags could easily do so profitably
**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** FDA Breakthrough Device Designation FDA TAP program inclusion FDA MDSAP certification FDA IDE’s for five cancers and counting Including FDA PHASE 3 completion for one indication in H1 2026 And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) FDA approval for commercial factory in the US, with other factories built and more in planing 100% tumor response rate in early FDA trials Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… Activates immune system 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy… and of course Japan where they are expected approval) Patents, IP and more…
He’s not wrong though. what about you, any thoughts or questions about DRTS?
Increases is an understatement, it multiplies the effectiveness. And yes this is a very bullish trial, I’m not sure if they will get paid straight up or if Merck would prefer a bigger scale strategic partnership, since this (as amazing as it is) is almost like a side effect of the DRTS treatment
So DRTS increases Keytruda’s effectiveness and they will get paid for this?
Keytruda is the #1 selling drug worldwide, all that despite only 19% of patients responding and only 5% showing complete response. Although a small sample size, but a combination therapy trial using Keytruda with a DRTS treatment (which has shown the ability to activate the immune system) has shown effectively 100% patient response and 50% complete response. If this holds up it’s an industry changer in and of itself, so the this is what they are potentially looking into with a larger trial and an FDA IDE to do so
**Upcoming catalyst for DRTS** **PMDA approval in Japan** Expected to be announced any day in the coming weeks **GBM FDA trial** Recently it was announced Alpha Tau has successfully treated the first GBM patient, historic news, with more patients and updates coming every month **FDA Pancreas trial** Earlier it was announced that Alpha Tau has successfully treated a Pancreatic Cancer patient as well, progress and updates from the Pancreas trial will be shared along the way **Phase 3 recruitment completion for cSCC** H1 2026 The early results are amazing **cSCC FDA approval submission** H2 2026 **New FDA trials launching** Most recently prostate, while next could be head & neck **Commercial manufacturing facility completion** Recently approved by the FDA **Keytruda trial for combination therapy** Updates from combination trials with Merck’s Keytruda, exploring systemic and metastatic potential **Other stock related events** Potential strategic partnerships or licensing deals, enabled by regulatory and manufacturing readiness. Investor re ratings, transitioning from pre revenue clinical stage to commercial oncology company is a major re-rating moment. Future label expansions leveraging existing approvals and platform scalability.
Is this bot only or could I request DRTS for the next post?
It’s actually very profitable, for example Keytruda was the top-selling drug worldwide, and the DRTS treatment is worldwide as well (already 50+ clinical sites worldwide) and is even in trials with Keytruda itself
This is the post for me, I see great value in penny stocks (if researched correctly) and I don’t play the in-n-out game, I invest to hold. My favorite pick for 2026 (and beyond) is DRTS. DRTS has everything lined up perfectly but somehow still under the radar. It has a strong cash position, experienced team, a revolutionary cancer treatment with FDA Breakthrough Device Designation that could treat the most high unmet needs cancers, expecting PMDA approval in Japan very soon and FDA approval next year as well.
Fair point, appreciate you bringing it up, although this is actually one of DRTS’s biggest strengths and advantages - how easy and not consuming it is to transport and treat with (could be sent in the mail and used in any doctor’s room)
I’m with you praying for any kind of advancement, whatever company it comes from is good with me. Just know the DRTS treatment is effective against all solid tumors, so although GBM is very exciting, DRTS has proven to be effective against dozens of other cancers (has yet to find a tumor that hasn’t responded), so please do the research I’m sure you’ll be encouraged!
Exciting times in cancer care (please god let’s see it all come to fruition) Extremely bullish on DRTS, a major catalyst is coming real soon with the PMDA approval in Japan, but even looking beyond that everything is lining up perfectly for 2026, with FDA approval on the table as well, a strong cash position, manufacturing facility completion and so much more
There are treatments going on in France today. France has given permission to start trials with $DRTS and the radiation concerns don’t seem applicable to alpha radiation. If this treats pancreatic cancer in France, any reluctance by the doctors will be overcome by the wave of demand. There are no other approved treatments that don’t devastate the patient through replumbing their entire body.
Should I go all in on DRTS or SLS?
Nope. If you’re new to penny stocks, you want to go to AI and ask the following: What is Chaikin Money Flow (CMF) and how does it look for $DRTS? This will show you whether there is still buying volume. If there’s buying volume, you are not too early - particularly if the CMF is rising.
This makes no sense. The healthy tissue around the tumor isn’t impacted at all. This is alpha radiation and it’s so safe that you can send it via FedEx without special protections. Please deep dive further on alpha radiation vs. more dangerous radiation. This is a HUGE advantage for $DRTS both in terms of safety and logistics.
From u/grigribs Look at his comments to DRTS. For example: Yes and no, the dose in the needles, is made to deliver 5uCi per gram of tumor. You're safe when you're far away, but for the doctor putting that in the brain, you need protections. If it can kill cancer cells, it's very active when you're close, you need protections for transport to the hospital, and to the surgery room. I'm not saying that it's very dangerous for the operator, but in my country, the transport, storage, and use of sources is highly regulated and requires specific procedures and precautions. I'm not sure that all neurosurgeons will be motivated by the results. It will take a long time to see if they will take a significant share of the treatment market.
I’m in SLS and DRTS. How is OTLK for you?
EXACTLY! DRTS solves the problem. GBM is a solid cancer and all cancer tumors have dna strands that can be broken with alpha radiation. That’s the power of Alpha Tau’s DaRTS tech. Once the dna helix is broken, two things happen: 1. The cancer can’t spread; and, 2. The body learns how to fight future tumors. I am insanely bullish!
SLS. Technically DRTS too but you asked for 1
I’m long on $DRTS, targeting $12 after getting through a forest at $10. Do you have a target for $SLS?
Split my bet between SLS and DRTS. Not a lot, about $5k total. Hopefully we all have a nice 2026
That’s great insight, although that’s exactly one of the DRTS strengths. The radiation dose is so low and controlled, that it could be sent in the mail and treated in any doctor’s room.
That happens alot with biotechs. Biotechs can 10x in a year months and can also drop 90% in a day! I'm hoping SLS and DRTS are 10x a year from now.😗
**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** FDA Breakthrough Device Designation FDA TAP program inclusion FDA MDSAP certification FDA IDE’s for five cancers and counting Including FDA PHASE 3 completion for one indication in H1 2026 And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) FDA approval for commercial factory in the US, with other factories built and more in planing 100% tumor response rate in early FDA trials Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… Activates immune system 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy…) Patents, IP and more…
**Upcoming catalysts for DRTS** **PMDA approval in Japan** Expected to be announced any day in the coming weeks **GBM FDA trial** Last week it was announced Alpha Tau has successfully treated the first GBM patient, historic news, with more patients and updates coming every month **FDA Pancreas trial** Earlier it was announced that Alpha Tau has successfully treated a Pancreatic Cancer patient as well, after successfully completing a Pancreatic Cancer study with tens of patients in Canada. Progress and updates from the Pancreas trial will be shared along the way as well **Phase 3 recruitment completion for cSCC** H1 2026 The early results are amazing **cSCC FDA approval submission** H2 2026 **New FDA trials launching** Most recently prostate, while next could be head & neck **Commercial manufacturing facility completion** Recently approved by the FDA **Keytruda trial for combination therapy** Updates from combination trials with Merck’s Keytruda, exploring systemic and metastatic potential **Other stock related events** Potential strategic partnerships or licensing deals, enabled by regulatory and manufacturing readiness. Investor re ratings, transitioning from pre revenue clinical stage to commercial oncology company is a major re-rating moment. Future label expansions leveraging existing approvals and platform scalability.
Every day is a day closer to Alpha Tau Medical getting approved in Japan [DRTS]
DRTS for me as well (sent you an invite to the DRTS subreddit)
GANX and DRTS is my portfolio til 2026
still holding my DRTS and CVU calls. Most other positions are cooked. Trading pennystocks works surprisingly well
Keep accumulating DRTS
Listen me out $DRTS Plz you guys just need five minutes to read about this company.
DRTS is a medical device, not a drug
Definitely agree to disagree. If you really believe this is a winner in the next year, don't buy the stock, buy the warrants that expire March 2027 for under $.50. I have been in biotech for a long time. Have made over $1M on one and multiple 6 digit winner's. I have done enough research on DRTS to know it's not anywhere near CADL. Again not knocking DRTS, but investigational studies are just that. Success will bring on larger studies that cost a lot more money. In the end, it will be about extending life beyond current standard of care therapies. CADL which has an SPA, also has fast track, orphan drug and RMAT designations from the FDA. All trials have extended life significantly beyond standard of care, the gold standard for approval. I have over 200k invested. It uses your bodies own immune system to destroy the cancer. No radiation, no side effects. It has been shown to eliminate cancer that has metatisied from it original site. Again, it has a successful phase 3 of over 700 patients that extended life over standard of care therapies that took 12 years to complete. It doesn't get any better than that. They are submitting the BLA to the FDA in 2026.
Agree to disagree. First of all, sadly, there are enough cancer cases for many companies to be successful (please god let’s get to the day that a company could have a cancer treatment but the competition for good treatments outweighs the need for them) Secondly, DRTS is in phase 3 of the FDA with five IDE’s going on, expecting PMDA approval any day now, have all the cash on hand etc etc, the risk is almost nonexistent while the reward could be anywhere between 10-100+ per share (with 10 coming in the next quarter and 100+ coming after)
They are going after the same indications. CADL is years ahead of DRTS. I am not saying DRTS won't be successful, but it's way to early back up the truck. The risk reward between the two greatly favors CADL.
DRTS is not a drug, it’s a medical device
DRTS has the PMDA approval coming up fast
Always happy to see a DRTS mention, thanks for posting about CABA and sharing all these positions and reasoning, also you got the M and A hunter active which is always a plus for everyone following
No worries- with how often it happens on the various penny stock communities I don't blame you, I try not to P&D anything. I am interested in squeeze plays if I like the setup/potential but this wasn't that. I swing trade BTC adjacent stocks and jump in on catalysts momentum trades. Normally if I'm in a biotech it's because I like the trend line for it. CABA, RVPH, and FEMY are my favorites rn pennywise and I have PSTV and DRTS but with exception of FEMY I keep those positions to 1-2%. Have some other higher biotechs like CRMD and ABT (I like ABT for its relatively steady growth and think the exact acquisition is a good move as exact also had acquired genomic health in 2019. oncotype dx and cologuard are regularly used at Cleveland clinic and I could see ABTs global presence speeding growth/usage of these once they get regulatory approvals through)
Sorry I got this confuswd with a different post. I am assuming DRTS is not a squeeze play but a buy the rumor sell the news pump and dump play?
Hmm what makes you say DRTS will go up by itself. Both of these scenarios need volume regardless. Have you done any DD on dilution risk and convertable notes or warrants etc. Not trying to argue just curious.
All very interesting, but the difference between SGBX and DRTS is that for SGBX you gotta put in all this work (for it to maybe work) while DRTS will do the work for you
DRTS, expecting PMDA approval
yeah if it gets to 500 or so it would be worth it. too much per share to tie up that amount of cash. you won't make much. better to find a small cap like POET or DRTS
I agree that the future overall looks pretty bright for DRTS. One thing I always struggle determining with companies like DRTS though is what's the likelihood that they will need a cash infusion that will effectively dilute the values of shares. Any ideas regarding that?
I’m open to anyone trying to prove otherwise, but DRTS is just sitting there with the upcoming PMDA approval coming waiting for anyone to buy and enjoy the potential gains
**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** FDA Breakthrough Device Designation FDA TAP program inclusion FDA MDSAP certification FDA IDE’s for **five** cancers and counting **FDA PHASE 3** completion for one indication in H1 2026 FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) FDA approval for commercial factory in the US, with other factories built and more in planing 100% tumor response rate in early FDA trials Effective against all tumor types, including high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… Activates immune system response **50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) Patents, IP and more…
**Upcoming catalyst for DRTS:** PMDA approval in Japan (should be as soon as before EOY) Just announced successful treatment of first GBM patient (further results and patients to come) Pancreas study progress and results (first patient was successfully treated as well) Phase 3 recruitment completion for cSCC New FDA trials launching (most recently prostate while next could be head & neck) Commercial manufacturing facility completion (recently approved by the FDA)
DRTS at this price is a no brainer
DRTS biggest bargain on the market, PMDA approval gonna hit hard
100% agree on DRTS. CVU... meh.
just noise today, still not selling DRTS and CVU
hey at least POET and DRTS was bought at a bargain
It’s amazing that DRTS still doesn’t get mentioned if I’m not the one mentioning it
Im in GANX at 2.90 ill look into DRTS
DRTS keeps going, will not sell
Im in GANX and DRTS and locked in profits, now just waiting to see what the future holds
Any thoughts on MNTS, ADTX, JMG, DRTS
DRTS is making big movements, something to keep your eye on
Not financial advice but may be worth looking into throwing 50% on PLBY and 50% on DRTS
What is going on with this $DRTS stock? I saw the overnight went through the roof. The volume is going up and every week there’s another success story. Is this a breakout?
What I meant (failed to mention correctly) is that the Pancreatic Cancer market is a larger percentage of the overall cancer market in Japan. In the US there are ~65K new Pancreatic cancer cases annually, while in Japan that is ~2.5X smaller there are ~50K new Pancreatic cancer cases annually It’s important because specifically Pancreatic cancer had no real treatment to date, while it’s DRTS’s bull case to commercialize it, with good results to date The upcoming PMDA approval also means Pancreatic cancer patients could ask for the DRTS treatment To my understanding the reasoning for the percentage difference is Japan has one of the world’s oldest populations, while pancreatic cancer is heavily age-dependent and less driven by lifestyle than many other cancers
Also OP if it’s ok that I add, sadly the Japanese cancer market is larger percentage wise than you’d think, so hopefully DRTS could save many lives in Japan (and by doing so having a strong business)
Agree that immunotherapies require caution or really investing anywhere within the biotech industry requires caution. That said, DRTS's solution is a radiotherapeutic, not an immunotherapy. This is exciting because the efficacy of their treatment relies on physics rather than biological interactions like immunotherapies rely on. This allows the company to use the same device to target all solid tumor cells - GBM is not the primary indication for the company, but their device should work just as well treating GBM as other cancer types.
DRTS has many catalysts lined up: Yesterday successfully treated 1st GBM patient (IDE will continue and results will come) PMDA approval in Japan (near term, could be as soon as before EOY) Pancreas study progress and results (first patient was successfully treated) Phase 3 recruitment completion for cSCC New FDA trials launching (most recently prostate while next could be head & neck) Commercial manufacturing facility completion (recently approved by the FDA)
Exactly, although some treatments damage the surroundings of the tumor, denying the body the ability to get to know the cancer cells. DRTS spares the health tissue, and allows the natural occurrence and T cells activity to take place, with evidence of the body then taking these learnings and attacking cancer cells elsewhere in the body. Would you like me to give some examples?
CVU and DRTS were the right decision, my DRTS options already up 250% https://preview.redd.it/0p1oussni96g1.jpeg?width=471&format=pjpg&auto=webp&s=28db3ddd385b6a92154eee01272a45bb41cc83a9
First of all I’m 100% with you on the beat cancer front, that’s what’s really exciting about it (it just happens to be that if it is successful at saving millions of people it will then make investors millions of dollars). And on the FDA front, the FDA loves DRTS. They just granted them their FIFTH simultaneous IDE. They awarded them with Breakthrough Device Designation. Accepted them into the TAP program. Certified them with the MDSAP. And more…
DRTS up 5% post-market, this can become interesting the next days.
Agreed! And what has me excited by DRTS, although it applies to other radiotherapeutics as well, is that the efficacy comes down more to physics and less to the individual biological interactions.
The ceiling is really high, the treatment is effective for all solid tumors, with dozens successfully tested in pre clinical trials (yet to find a tumor that doesn’t respond, including breast, lungs, pancreas, prostate, skin, head and neck etc) and 5(!) currently active IDE’s If we take just pancreas for example, and only in the US, that’s 60K new annual cases that would need the DRTS treatment, with a cost basis of say 100K$ that’s billions in annual revenue from one indication alone and only in the US. With a market cap of only ~350M… price target could be 10$+ easily (in the near term say a few months from now)
They’re both early so it’s hard to directly compare without more data. I prefer the alpha radiation approach from DRTS, I think it will prove to be highly destructive to tumor cells without being impacted by the tumor’s micro environment and with no impact to surrounding healthy tissue. As an investor, taking the IDE pathway to approval versus the IND pathway is also a significant difference, although PSTV is well ahead in the development process for GBM…
PSTV has similar aproach as DRTS. The difference is the radiation source used Radium-224 vs Rhenium-186. Rhenium-186 has an advantage with its low dose Gamma Rays that can be used for imaging. I believed PSTV will be heading in similar direction as DRTS and its still below $1.